Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AVB-S6-500 + Pegylated liposomal-doxorubicin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AVB-S6-500 | AVBS6500|AV S6 500 | AVB-S6-500 is a fusion protein comprised of human IgG1 linked to the extracellular domain of Axl, which binds to growth arrest-specific protein 6 (GAS6), potentially resulting in decreased downstream signaling and reduced tumor growth (PMID: 32148495, PMID: 31599479). | ||
Pegylated liposomal-doxorubicin | Doxil | ATI-0918|CAELYX | Chemotherapy - Anthracycline 11 | Doxil (pegylated liposomal doxorubicin) is doxorubicin (intercalates into DNA, disrupting DNA replication) encapsulated, which within a liposome allows better penetration into tumors, decreases toxicity, and increases the period of effectiveness, and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03639246 | Phase Ib/II | AVB-S6-500 + Paclitaxel AVB-S6-500 + Pegylated liposomal-doxorubicin Paclitaxel Pegylated liposomal-doxorubicin | Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |